Singapore’s Enleofen sells biotech platform rights to pharma major Boehringer

Singapore’s Enleofen sells biotech platform rights to pharma major Boehringer

Singapore-based biotech company Enleofen Bio is selling the worldwide exclusive rights of its biotech platform, Eneleofen’s preclinical interleukin-11 (IL-11), to global pharma major Boehringer Ingelheim, according to a press statement.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter